Projects per year
Personal profile
Biography
Dr Sifei Han is NHMRC (National Health and Medical Research Council) Early Career Fellow at the Monash Institute of Pharmaceutical Sciences, Monash University. After completing his undergraduate study at Nanjing University (2006) and master’s study at the Shanghai Institute of Materia Medica (2009), Sifei relocated to Australia in 2010 for PhD training under the supervision of Professor Christopher Porter and Dr Natalie Trevaskis at Monash Institute of Pharmaceutical Sciences. Following that he started working as a post-doc research fellow since 2014.
Under the mentorship of Professor Christopher Porter and through close collaboration with MIPS scientists in the theme of Medicinal Chemistry, Dr Han's research has focused on using lipid-mimetic prodrug strategies to enhance drug transport to the lymphatic system. This promotes the delivery of immunomodulatory drugs to the target site – the lymphatics, providing opportunities to improve treatment of conditions such as (auto)immune disorders where the lymphatic system is closely involved. Via redirecting drug transport to the lymphatics rather than the blood stream after oral absorption, the prodrug approach also enables the oral bioavailability of drugs and drug candidates that are normally subject to significant hepatic first-pass metabolism. Recently his research interests have expanded to using ionic liquids (lipophilic salts) and lipid based formulations to enhance the absorption of poorly water soluble drugs, and to develop the models and techniques to probe the underlying interactions. His research has been well recognised by international peers, exemplified by several high impact journal publications and prestigious awards. In addition to fundamental research outcomes, two patent applications have been filed attributing to the novelty and potential to translation into clinical products.
Research interests
- Lymphatic drug transport
- Prodrug design and development
- Oral drug delivery, bioavailability enhancement
- Lipid-based formulation and ionic liquids design and assessment
- Lymph-directing strategies with related disease areas including cancer, immune disorders and metabolic syndrome
Community service
Dr. Sifei Han is the elected President of Chinese Association of Professionals and Scholars, Australia (CAPS Australia). CAPS represents more than 1200 Chinese research scholars, entrepreneurs and visiting scientists with broad academic backgrounds, and bridges academic and cultural exchanges between Australia and China.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
External positions
President, Chinese Association of Professionals and Scholars (Australia)
Mar 2017 → …
Research area keywords
- Lymphatic Drug Transport
- Prodrug
- Oral Drug Delivery
- Drug Development
- Lipid-Based Formulation Design
- Drug Optimisation
Collaborations and top research areas from the last five years
Projects
- 1 Finished
-
A biomimetic prodrug platform to enable oral bioavailability and target lymphatic disease
1/07/17 → 30/06/21
Project: Research
-
Transformation of biopharmaceutical classification system class I and III drugs into ionic liquids and lipophilic salts for enhanced developability using lipid formulations
Williams, H. D., Ford, L., Lim, S., Han, S., Baumann, J., Sullivan, H., Vodak, D., Igonin, A., Benameur, H., Pouton, C. W., Scammells, P. J. & Porter, C. J. H., 2018, In: Journal of Pharmaceutical Sciences. 107, 1, p. 203–216 14 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile45 Citations (Scopus) -
Lymphatic transport and lymphocyte targeting of a triglyceride mimetic prodrug is enhanced in a large animal model: studies in greyhound dogs
Han, S., Hu, L., Gracia, G., Quach, T., Simpson, J. S., Edwards, G. A., Trevaskis, N. L. & Porter, C. J. H., 3 Oct 2016, In: Molecular Pharmaceutics. 13, 10, p. 3351-3361 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile35 Citations (Scopus) -
Constitutive triglyceride turnover into the mesenteric lymph is unable to support efficient lymphatic transport of a biomimetic triglyceride prodrug
Han, S., Hu, LJ., Quach, T., Simpson, J., Trevaskis, N. & Porter, C. J. H., 1 Feb 2016, In: Journal of Pharmaceutical Sciences. 105, 2, p. 786-796 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile19 Citations (Scopus) -
Glyceride-mimetic prodrugs incorporating self-immolative spacers promote lymphatic transport, avoid first-pass metabolism, and enhance oral bioavailability
Hu, L., Quach, T., Han, S., Lim, S. F., Yadav, P., Senyschyn, D., Trevaskis, N. L., Simpson, J. S. & Porter, C. J. H., 2016, In: Angewandte Chemie - International Edition. 55, 44, p. 13700 –13705 6 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access60 Citations (Scopus) -
Profiling the role of deacylation-reacylation in the lymphatic transport of a triglyceride-mimetic prodrug
Han, S., Hu, L., Quach, T., Simpson, J. S., Trevaskis, N. & Porter, C. J., 2015, In: Pharmaceutical Research. 32, 5, p. 1830-1844 15 p.Research output: Contribution to journal › Article › Research › peer-review
30 Citations (Scopus)